E6 TCR

Drug Profile

E6 TCR

Alternative Names: anti-HPV-16 E6 TCR; HPV-16 E6 TCR gene therapy

Latest Information Update: 06 Apr 2017

Price : $50

At a glance

  • Originator Kite Pharma; National Cancer Institute (USA)
  • Class Cell therapies; Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action Gene transference; Human papillomavirus E6 T cell receptor expression modulators; T-cell receptor antigen antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Anal cancer; Cervical cancer; Oropharyngeal cancer; Penile cancer; Vulvovaginal cancer

Most Recent Events

  • 06 Apr 2017 Discontinued - Phase-II for Anal cancer, Cervical cancer, Oropharyngeal cancer, Penile cancer, and Vulvovaginal cancer (Recurrent, Refractory metastatic disease, Second-line therapy or greater) in USA (IV), because E6 TCR was not listed on Kite Pharma pipeline April 2017
  • 09 Apr 2016 National Cancer Institute suspends patients enrolment in a phase II trial for Cervical, Vulvovaginal, Penile, Anal and Oropharyngeal cancer (Recurrent, Refractory metastatic disease, Second-line therapy or greater) in USA (NCT02280811)
  • 31 Oct 2014 Phase-II clinical trials in Cervical cancer (Recurrent, Refractory metastatic disease, Second-line therapy or greater) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top